The medications everolimus and sirolimus, which are inhibitors of the mechanistic target of rapamycin (mTOR) pathway, have shown promise in reducing the size of brain, kidney and lung tumors associated with TSC [10]. Here, MTOR is linked to tuberous sclerosis.